A late-stage study of Merck's pipeline candidate doravirine, an antiretroviral therapy, found the drug to be effective and well-tolerated, according to data presented at the annual Conference on Retroviruses and Opportunistic Infections.
Study: Antiretroviral drug candidate effective, well-tolerated
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.